Goldman Sachs Views Lab Stocks as Attractive, Neutral on Diagnostics; LabCorp (LH) Top Pick, Myriad (MYGN) the Bottom

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. META
6. TSLA
7. RTX
8. SMCI
9. S
10. COF

Go back to Goldman Sachs Views Lab Stocks as Attractive, Neutral on Diagnostics; LabCorp (LH) Top Pick, Myriad (MYGN) the Bottom

Qiagen (QGEN) Agrees to Acquire STAT-Dx

January 31, 2018 4:35 PM EST

QIAGEN N.V. (NYSE: QGEN) announced today it has entered into an agreement to acquire STAT-Dx, a privately-held company developing the next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes using a novel system based on real-time PCR technology and proven QIAGEN chemistries.

The... More

Qiagen (QGEN) Tops Q4 EPS by 2c, Beats on Revenues; 'Sets FY18 Outlook for Further Growth in Adj. Net Sales & Adj. EPS'

January 31, 2018 4:15 PM EST

Qiagen (NASDAQ: QGEN) reported Q4 EPS of $0.43, $0.02 better than the analyst estimate of $0.41. Revenue for the quarter came in at $396.6 million versus the consensus estimate of $393.33 million.

Solid Q4 results as QIAGEN achieves full-year 2017 targets: Q4 2017: Net sales $396.9 million (+8% actual, +5% CER);... More